Metraipolis › archive › dc_67387fe694f7

Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation… — Europe PMC PMID:41874648

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41874648
DOI
10.1007/s00262-[numero omesso]-9
License (as archived)
solo-consultazione
Archived
2026-10-08T05:17:11.040Z
SHA-256 of the archived text
83cf3d34e94444a27989853b717047cac6e341a36d6a5544501ce757f1f038c4
Stable URL of this page
https://metraipolis.com/documento/dc_67387fe694f7

How to cite

Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation… — Europe PMC PMID:41874648 — Europe PMC (en), https://europepmc.org/article/MED/41874648 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_67387fe694f7 (Metraipolis archive dc_67387fe694f7, sha256 83cf3d34e94444a27989853b717047cac6e341a36d6a5544501ce757f1f038c4)
BibTeX
@misc{dc67387fe694f7,
  title = {Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation… — Europe PMC PMID:41874648},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41874648},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_67387fe694f7; sha256 83cf3d34e94444a27989853b717047cac6e341a36d6a5544501ce757f1f038c4},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41874648. Agents can read the archived copy with the MCP tool read_document.